TO REGISTER, CLICK HERE »
You can save an extra 10% off the current rate by using code D10-999-JDS20.
Master the Skills Needed to Overcome the Challenges of Modern Paragraph IV Litigation.
ACI is proud to present this master symposium each fall as a companion to its flagship Paragraph IV Disputes conference, and is honored to work and interact with this unique group of pharmaceutical executives and legal professionals. This conference seeks to capture the nuances of this multifarious area of the law, as well as provide answers to your most pressing questions. We strive to serve the legal and business needs of both branded and generic drug makers by providing practitioners with practical information on cutting edge trends that affect both substantive and procedural matters of significance to IP stakeholders.
Over the course of three days, our faculty of esteemed speakers will outline the curves and crevices of the current Hatch-Waxman litigation landscape, review the current statutory framework that is designed to balance the competing interests of branded pharmaceutical companies and companies that manufacture generic alternatives, and consider the introduction of several new bills, and more importantly, evaluate their potential impact. They will also describe the types of matters they encounter citing their own experiences litigating Hatch-Waxman cases, including navigating FDA and FTC regulatory issues, working with scientific experts, the application of patent law, and the evolution of Paragraph IV litigation strategies.
Download the conference brochure here »
TOP REASONS TO ATTEND:
CRITICAL INSIGHTS FROM:
- United States District Court
- US Patent and Trademark Office (USPTO), Patent Trial and Appeal Board
- Federal Trade Commission
TOWN HALL Q&A: Exclusive Insights from ACI’s Hatch-Waxman Series Advisory Board
REGULATORY THINK TANK: The Effect of the FDA Initiatives on Generic Drug Access and ANDA Litigation
Click here to learn more about this conference »
Meet our Co-Chairs
|
Ryan M. Daniel
Acting Chief Patent Counsel,
Fresenius Kabi USA, LLC
“I’m excited to participate in ACI’s 2019 Paragraph IV Conference here in Chicago. It’s a welcome opportunity to engage with colleagues regarding the evolving landscape of Hatch-Waxman law and the pharmaceutical industry.”
|
Andrea Hutchison
Associate General Counsel, IP Litigation
Gilead Sciences
“ACI’s Paragraph IV Conference series offers a great opportunity to convene and exchange ideas with subject matter experts from all over the country. I am delighted to return to Chicago and to meet with our many talented Hatch-Waxman litigators and colleagues in the industry.”
|
Obtain insights from key industry stakeholders on the design and execution of effective Paragraph IV litigation strategies:
- AbbVie
- Akorn Pharmaceuticals
- Amneal Pharmaceuticals
- Avanir Pharmaceuticals
- Eagle Pharmaceuticals
- Eli Lilly & Company
- Fresenius Kabi USA
- Genentech
|
- Gilead Sciences
- Glenmark Pharmaceuticals
- Ironwood Pharmaceuticals
- Jounce Therapeutics
- Merus US, Inc.
- Mylan
- Takeda
|
Click here to see the speakers list »
REGISTER NOW and save an extra 10% off the conference by using code D10-999-JDS20.
AmericanConference.com/PIVDisputesChicago | 888 224 2480
*Discount is valid for new registration only and it’s not applicable for workshops.
